Westminster Health Forum

Since lockdown, we have been organising our full programme of conferences online. We will continue online until further notice, to ensure we play our part in helping our employees and delegates to remain safe during this time. We are pleased that so many key stakeholders, policymakers and other interested parties - both old friends and new delegates - are taking up the opportunity to discuss public policy issues and network at our impartial seminars. New events are coming on to our conference programme all the time. So there are plenty of opportunities for you to join us if you haven’t already, from wherever you are. For booking-related queries, or information on speaking, please email us at info@forumsupport.co.uk or contact us using one of the following numbers: +44 (0)7951044809 / +044 (0)7503591880 / +44 (0)7538736244.

The future for UK regulation of medicines, medical devices and clinical trials - transparency and public trust, safety and enforcement, and support for innovation

Morning, Thursday, 16th July 2020

Online Conference


***Full-scale policy conference taking place online***

This conference will be a timely opportunity to discuss the future regulation of medicines, clinical trials and medical devices in the UK.


The agenda:

  • Priorities for regulation and the role of the MHRA;
  • Meeting the challenge of regulating and developing medicines during the Covid-19 pandemic;
  • Stakeholder priorities for medicine regulation - safety, research integrity and innovation:
    • developing a regulatory ecosystem that supports innovation, provides regulatory certainty, and is transparent,
    • research integrity, skills and international collaboration,
    • key issues for patient care - research, communication and access to treatment,
    • developing methods and technologies to ensure safe and effective medicines, and
    • prioritising support for the uptake and adoption of innovations.
  • The future for collaboration with the EU, and the UK’s relationship with the EMA ;
  • Using technology to tackle irresponsible medical ads - partnership with online platforms and statutory enforcement partners; and
  • Key issues for ensuring quality in clinical trials and the medicine approval process - research integrity, public trust and workforce development

Developments that are relevant to the discussion:


Areas for discussion at this conference:

  • The Medicines and Medical Devices Bill - and its provisions for:
    • ensuring the safety of human medicines and devices,
    • access to and availability of human medicines and medical devices, and
    • making the UK an attractive place in which to conduct clinical trials, supply human medicines or develop and supply devices.
  • Healthcare regulation - the future landscape, and role of the UK in European regulatory procedures - including key issues for maintaining access, innovation and the supply of medicines to the UK;
  • Clinical trials - looking at priorities for the research transparency group, and key issues including:
    • priorities for research and funding in a changing landscape,
    • what is needed from regulation to ensure the transparency of clinical trials - and how improvements in transparency will be measured,
    • maintaining the trust of the public and clinicians, and encouraging engagement, and
    • driving adoption and preventing variation.
  • Safety of medicines and technologies - key issues for improvement, looking at:
    • priorities for developing safe and effective treatments, and
    • awareness raising and training in the administration of treatments  for staff, patients and the general public and the developing role of patient safety specialists.
  • Enforcement and sanctions - how non-compliance with regulations should be tackled, including:
    • proposals in the Medicine and Medical devices Bill for a enforcement notices with criminal sanctions for breaches,
    • how individuals affected by breaches to legislation will be able to bring civil proceedings forward, and
    • what more can be done to deter the manufacture and supply of counterfeit products in the future.
  • Innovation - ensuring the regulatory framework fosters development of new medicines and technology, including:
    • priorities for meeting ambitions around scalability and adoption of new products and devices from successful clinical trials to rollout;
    • progress of the Accelerated Access Collaborative (AAC) - set up to speed up the uptake of pioneering treatments,
    • factors for effective adoption, looking at clinician trust, the role of AHSNs and limiting variation,
    • improving the speed of the regulatory approval process, and
    • further support could be provided to innovators, with the NHS Long Term Plan emphasising the importance of innovation and bringing the benefits to patients.

Policy officials attending:

Our forums are known for attracting strong interest from policymakers and stakerholders.


It’s certainly the case with this one. Places have been reserved by officials from the Medicines and Healthcare Products Regulatory Agency; the Department of Health and Social Care; BEIS; the Department for International Trade; the Government Legal DepartmentHM Revenue & CustomsHM Treasury and The Scottish Government.


This is a full-scale conference taking place online***

  • full, four-hour programme including comfort breaks - you’ll also get a full recording to refer back to
  • information-rich discussion involving key policymakers and stakeholders
  • conference materials provided in advance, including speaker biographies
  • speakers presenting via webcam, accompanied by slides if they wish, using the Cisco WebEx professional online conference platform (easy for delegates - we’ll provide full details)
  • opportunities for live delegate questions and comments with all speakers
  • a recording of the addresses, all slides cleared by speakers, and further materials, is made available to all delegates afterwards as a permanent record of the proceedings
  • delegates are able to add their own written comments and articles following the conference, to be distributed to all attendees and more widely
  • networking too - there will be opportunities for delegates to e-meet and interact - we’ll tell you how!

Full information and guidance on how to take part will be sent to delegates before the conference



Keynote Speaker

Jonathan Mogford

Policy Director, MHRA

Keynote Speakers

Professor Jean McHale

Professor of Healthcare Law, and Director of the Centre for Health Law Science and Policy, University of Birmingham

Jonathan Mogford

Policy Director, MHRA

Jane Eldridge

Head of Casework, Advertising Standards Agency

Dr Aldo Faisal

Reader in Neurotechnology, Department of Bioengineering and Department of Computing, Imperial College London and Director, UKRI Centre in AI for Healthcare, Imperial College London

Chairs

Daniel Zeichner MP

Anne Marie Morris MP

Speakers

Juliet Tizzard

Director of Policy, Health Research Authority

Erin Brooks

Head of Regulatory, Roche

Dr Jan Turner

Director, Safer Medicines Trust

Neil Bennett

Director of research, Action Duchenne

Eugene Pozniak

Managing Director, Siyemi Learning and Programme Director, European CME Forum

Patrick Stephenson

Director of Innovation and Healthcare, Fujitsu